Broad Institute
MAY 14, 2024
“Bill Studier’s development of T7 phage RNA polymerase for use in preparing RNA templates for multiple uses in research labs worldwide has been a truly revolutionary technical advance for the entire field of molecular biology,” said Joan Steitz, the Sterling Professor of Molecular Biophysics and Biochemistry at Yale University.
The Pharma Data
JANUARY 13, 2021
Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. based Mogrify Limited expanded its research collaboration with MRC Laboratory of Molecular Biology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
DrugBank
FEBRUARY 9, 2023
1 Present address: Functional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Denmark. With both paid and free academic licenses available, there are options to suit all of your research needs. 2 Cancer Program, Broad Institute of MIT and Harvard, USA.
Drug Target Review
FEBRUARY 28, 2024
Dr Rochlin earned a PhD in Molecular Biology and Genetics from Weill Cornell Medical College, conducting research at Sloan Kettering Institute, and a BA in Biology from the University of Pennsylvania. Normality sensing licenses local T cells for innate-like tissue surveillance. References Fichtner A, Ravens S, Prinz I.
Codon
FEBRUARY 13, 2024
Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. Crucially, it could also make them easier to license as therapeutic agents. There is also a growing body of successful treatments in the U.S., Phage therapies are sold at a pharmacy in Georgia.
The Pharma Data
JANUARY 18, 2021
Yesse Technologies’ core technology, the ORion21 genetic platform, is the product of over 30 years of fundamental research on the molecular biology of the sense of smell and is exclusively licensed from The City University of New York.
The Pharma Data
JANUARY 4, 2021
We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University. . Kiromic’s deep understanding of the tumor micro environment (TME) and the tumors’ escape and masking mechanisms led to development of a promising platform for chimeric antigen receptor therapy (CAR-T).
Expert insights. Personalized for you.
84 
Let's personalize your content